Page 4 - Tecentriq News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tecentriq. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tecentriq Today - Breaking & Trending Today

Roche: Phase III Study Of Tecentriq Combination In Hepatocellular Carcinoma Meets Primary Endpoint

SOUTH SAN FRANCISCO (dpa-AFX) - Pivotal Phase III IMbrave050 study, which investigated Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma or HCC at high risk of recurrence ....

European Medicines Agency , Drug Administration , Roche Group , More Such Health News ,

F. Hoffmann-La Roche Ltd: Roche's Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial

Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free ....

United States , Birgit Masjost , Levi Garraway , Loren Kalm , Sabine Borngr , Nathalie Altermatt , Gerard Tobin , Bruno Eschli , Drug Administration , European Medicines Agency , Roche Group , Head Of Global Product Development , Roche Group Media Relations , Pivotal Phase , Chief Medical Officer , Global Product , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Reviews Disease ,

F. Hoffmann-La Roche Ltd: European Commission approves Roche's Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer

In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq ....

United Kingdom , United States , Israel General , Comunidad Autonoma De Cataluna , Nathalie Meetz , Levi Garraway , Sabine Borngr , Gerard Tobin , Bruno Eschli , Birgit Masjost , Enriqueta Felip , Loren Kalm , European Commission , Head Of Global Product Development , Hebron Institute Of Oncology , Roche Group , Roche Group Media Relations , American Cancer Society , Chief Medical Officer , Global Product , Professor Enriqueta Felip , Thoracic Cancer Unit , Hebron Institute , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Cancer Society ,

Roche's Tecentriq Gets EC Nod As Adjuvant Treatment For Certain People With Early-stage NSCLC

SOUTH SAN FRANCISCO (dpa-AFX) - Roche Holding AG's (RHHBY) blockbuster drug Tecentriq has been approved by the European Commission for yet another lung cancer indication - this time, as an adjuvant ....

United Kingdom , Levi Garraway , European Commission , Head Of Global Product Development , Roche Holding , Chief Medical Officer , Global Product ,

ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb's iPREDICT Phase IIb Study

LOS ANGELES, June 8, 2022 /PRNewswire/ ImaginAb Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals ....

British Columbia , Jim Pallotta , William Le , Cycad Group , Roche Group , Imaginab Inc , Parker Institute For Cancer Immunotherapy , Raptor Group , Prnewswire Imaginab Inc , Non Small Cell Lung Cancer , Merkel Cell , Renal Cell Carcinoma , Adage Capital , Norgine Ventures , Parker Institute ,